BSN: Schering-Plough announces phase II-IIIdata for Corifollitropin Alfa

Improve Your Rank!

People, Speakers

Abstracts, Posters

What's My Rank?
      What's My Popularity Score?
      In My Orgs?
      In My Specialities?
      In My Geography?
      In My Age?

My Mentors, Collaborators,
Associates, Peers, Buddies

Keep Me Up To Date
Specialty, Keyword,
Geography

People Making News

Latest Research From
Meetings

Recent Postings

People of Consequence (40202)

1. Richard M. Satava
University of Washington
2. Adam P Dicker
Thomas Jefferson University
3. Lena Specht
Copenhagen University
4. Richard G. Pestell
Kimmel Cancer Center
5. Warren M. Jackman
University of Oklahoma

Orgs of Consequence (10419)

1. University of California
2. Harvard University
3. Mayo Clinic
4. National Institutes of Health, Chemical Genomics Centre
5. M. D. Anderson Cancer Center

Terms of Consequence

1. Cells
2. Cancer
3. Genetics
4. Molecular
5. Proteins

Schering-Plough announces phase II-IIIdata for Corifollitropin Alfa

Saturday, July 4

Schering-Plough announced results from the Phase III ENGAGE clinical trial demonstrating that a single injection of corifollitropin alfa, first in the class of sustained follicle stimulants, achieved similar efficacy to recombinant follicle stimulating hormone (rFSH) given once daily for seven days.

http://www.biospectrumasia.com/content/030709OTH9880.asp

Comments

About Us | Privacy Policy | Site Map | FAQs | Advertise With Us | Community

BiotechScienceNews.com promotes research and ranks life scientists working in the life science spectrum involving biotechnology,
drug discovery, genomics, microbiology, neuroscience, medicine, pharmacology, cell biology, and molecular biology.